Immunic (IMUX) Accumulated Expenses (2013 - 2026)

Immunic has reported Accumulated Expenses for 14 years, with the latest figure at $22.4 million in Q1 2026.

• Quarterly Accumulated Expenses rose 22.65% year-over-year to $22.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.4 million (up 22.65% YoY) and the FY2025 annual result came in at $18.6 million, up 44.39% from the prior year.
• Accumulated Expenses improved to $22.4 million in Q1 2026 per IMUX's latest filing, from $18.6 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $22.4 million in Q1 2026 and troughed at $5.7 million in Q2 2022.
• A 5-year average of $13.8 million and a median of $13.7 million in 2023 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses surged 133.71% in 2023, then slumped 30.81% in 2024.
• Over 5 years, Accumulated Expenses stood at $8.0 million in 2022, then surged by 133.71% to $18.7 million in 2023, then plunged by 30.81% to $12.9 million in 2024, then soared by 44.39% to $18.6 million in 2025, then grew by 20.31% to $22.4 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $22.4 million, $18.6 million, and $19.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.